within Pharmacolibrary.Drugs.ATC.N;

model N02AA05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 1.3333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 15.0,            
    Vdp             = 0.0012,
    k12             = 0.6,
    k21             = 0.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oxycodone is a semi-synthetic opioid analgesic used for the management of moderate to severe pain. It is a controlled substance, approved for medical use in many countries and commonly prescribed for post-operative pain, cancer pain, and chronic pain conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult male and female volunteers following a single oral dose administration.</p><h4>References</h4><ol><li><p>Lugo, RA, &amp; Kern, SE (2004). The pharmacokinetics of oxycodone. <i>Journal of pain &amp; palliative care pharmacotherapy</i> 18(4) 17–30. DOI:<a href=\"https://doi.org/10.1300/j354v18n04_03\">10.1300/j354v18n04_03</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15760805/\">https://pubmed.ncbi.nlm.nih.gov/15760805</a></p></li><li><p>Kibaly, C, et al., &amp; Cahill, CM (2021). Oxycodone in the Opioid Epidemic: High &#x27;Liking&#x27;, &#x27;Wanting&#x27;, and Abuse Liability. <i>Cellular and molecular neurobiology</i> 41(5) 899–926. DOI:<a href=\"https://doi.org/10.1007/s10571-020-01013-y\">10.1007/s10571-020-01013-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33245509/\">https://pubmed.ncbi.nlm.nih.gov/33245509</a></p></li><li><p>Szałek, E, et al., &amp; Murawa, P (2014). The pharmacokinetics of oral oxycodone in patients after total gastric resection. <i>European review for medical and pharmacological sciences</i> 18(20) 3126–3133. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25392115/\">https://pubmed.ncbi.nlm.nih.gov/25392115</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AA05;
